Global Blood Therapeutics (GBT) Stock Price Down 5.1% Following Insider Selling

Global Blood Therapeutics Inc (NASDAQ:GBT) dropped 5.1% on Monday after an insider sold shares in the company. The company traded as low as $57.25 and last traded at $57.72. Approximately 746,681 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 1,257,703 shares. The stock had previously closed at $60.80.

Specifically, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $36.55, for a total value of $109,650.00. Following the completion of the sale, the insider now owns 135,255 shares of the company’s stock, valued at approximately $4,943,570.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Perceptive Advisors Llc purchased 175,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was bought at an average cost of $38.00 per share, with a total value of $6,650,000.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 51,812 shares of company stock valued at $2,864,728. 5.30% of the stock is owned by insiders.

GBT has been the topic of several recent research reports. Zacks Investment Research raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Cowen reaffirmed a “buy” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a research note on Thursday, November 9th. Wedbush reaffirmed an “outperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Friday, December 15th. Nomura lifted their target price on shares of Global Blood Therapeutics to $91.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Oppenheimer set a $79.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $63.27.

The stock has a market cap of $2,797.25, a PE ratio of -22.64 and a beta of 4.78.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same quarter in the previous year, the business earned ($0.58) EPS. equities research analysts expect that Global Blood Therapeutics Inc will post -2.53 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in GBT. Jane Street Group LLC acquired a new position in Global Blood Therapeutics in the third quarter valued at about $200,000. Trexquant Investment LP acquired a new position in Global Blood Therapeutics in the third quarter valued at about $202,000. Dynamic Technology Lab Private Ltd acquired a new position in Global Blood Therapeutics in the third quarter valued at about $205,000. Raymond James Financial Services Advisors Inc. acquired a new position in Global Blood Therapeutics in the third quarter valued at about $230,000. Finally, First Republic Investment Management Inc. acquired a new position in Global Blood Therapeutics in the third quarter valued at about $237,000. 85.67% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thestockobserver.com/2018/02/05/global-blood-therapeutics-gbt-stock-price-down-5-1-following-insider-selling.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply